Immune tolerance therapy for inhibitors in haemophilia A

被引:0
|
作者
Oldenburg, J. [1 ]
机构
[1] Univ Klinikum Bonn, Inst Expt Hamatol & Transfus Med, Bonn, Germany
来源
HAMOSTASEOLOGIE | 2008年 / 28卷
关键词
Immune tolerance therapy; inhibitors; haemophilia A;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The development of inhibitors at start of therapy with factor VIII concentrates represent the most serious complication of haemophilia treatment. The only way to along lasting eradication of the inhibitor is the induction of immune tolerance. A successful immune tolerance therapy (ITT) is the precondition for a regular prophylactic treatment regime and subsequently safe life perspective with a good quality of life. All ITT protocols have been developed empirically without knowing the pathophysiological mechanisms. The guidelines of the Federal Chamber of Physicians (1), the German recommendations for ITT (2) and the consensus recommendations of an international working group (3) provide an important lead for the conduction of immune tolerance therapy.
引用
收藏
页码:S23 / S25
页数:3
相关论文
共 50 条
  • [31] Immune tolerance induction with human-cl rhFVIII in patients with severe haemophilia A and inhibitors
    Hall, G.
    Bhatnagar, N.
    Khair, K.
    Wilkinson, A.
    Belyanskaya, L.
    Liesner, R.
    HAEMOPHILIA, 2019, 25 : 93 - 93
  • [32] Rituximab as an adjuvant therapy to immune tolerance in a haemophilia A boy with high inhibitor titre
    Chuansumrit, A.
    Husapadol, S.
    Wongwerawattanakoon, P.
    Hongeng, S.
    Sirachainan, N.
    Pakakasama, S.
    HAEMOPHILIA, 2007, 13 (01) : 108 - 110
  • [33] Gene therapy for immune tolerance induction in hemophilia with inhibitors
    Arruda, V. R.
    Samelson-Jones, B. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (06) : 1121 - 1134
  • [34] Immune Tolerance Induction with Simoctocog Alfa (Nuwiq®) in Six Patients with Severe Haemophilia a and FVIII Inhibitors
    Bhatnagar, Neha
    Khair, Kate
    Liesner, Ri
    Wilkinson, Alice
    Belyanskaya, Larisa
    BLOOD, 2018, 132
  • [35] Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product
    Rangarajan, S.
    Jimenez-Yuste, V.
    Santagostino, E.
    HAEMOPHILIA, 2014, 20 (06) : E414 - E417
  • [36] Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors
    Unuvar, A.
    Kavakli, K.
    Baytan, B.
    Kazanci, E.
    Sayli, T.
    Oren, H.
    Celkan, T.
    Gursel, T.
    HAEMOPHILIA, 2008, 14 (02) : 315 - 322
  • [37] Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors
    Di Minno, Giovanni
    Coppola, Antonio
    Margaglione, Maurizio
    Rocino, Angiola
    Mancuso, Maria Elisa
    Tagliaferri, Annarita
    Linari, Silvia
    Zanon, Ezio
    Santoro, Cristina
    Biasoli, Chiara
    Castaman, Giancarlo
    Santagostino, Elena
    Mannucci, Pier Mannuccio
    HAEMOPHILIA, 2022, 28 (01) : 55 - 64
  • [38] Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study
    Rodriguez, V.
    Mancuso, M. E.
    Warad, D.
    Hay, C. R. M.
    Dimichele, D. M.
    Valentino, L.
    Kenet, G.
    Kulkarni, R.
    HAEMOPHILIA, 2015, 21 (05) : E369 - E374
  • [39] Late immune tolerance induction in haemophilia A patients
    Meeks, S. L.
    Chapman, R. L.
    Kempton, C.
    Dunn, A. L.
    HAEMOPHILIA, 2013, 19 (03) : 445 - 448
  • [40] Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors
    Kurth, M. A. H.
    Dimichele, D.
    Sexauer, C.
    Sanders, J. M.
    Torres, M.
    Zappa, S. C.
    Ragni, M.
    Leonard, N.
    HAEMOPHILIA, 2008, 14 (01) : 50 - 55